Physician profile
Paul V Benoit
NPI 1992781942
$2,504.45
in general payments reported to CMS, 2019-2025
24 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $28.88 · 2021: $216 · 2022: $170 · 2023: $272 · 2024: $600 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.77 | 2023-2025 | Durysta |
| Mallinckrodt Hospital Products INC. | $347.82 | 2023-2025 | Acthar |
| Astellas Pharma US INC | $282.28 | 2023-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $239.80 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $169.78 | 2019-2025 | Cequa |
| Horizon Therapeutics Plc | $105.13 | 2021-2023 | Tepezza |
| Dompe US, INC. | $103.34 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.16 | 2021 | |
| Alcon Vision LLC | $85.73 | 2021-2024 | Rocklatan |
| Ani Pharmaceuticals, INC. | $66.70 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Genentech USA, INC. | $60.05 | 2024-2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $50.67 | 2022 | |
| Alimera Sciences, INC. | $50.42 | 2019-2023 | Yutiq |
| Sandoz INC. | $34.51 | 2024 | Cimerli |
| Johnson & Johnson Surgical Vision, INC. | $31.64 | 2024 | Lipiflow System Activator II (Disposable |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.58 | 2024 | Eylea Hd |
| Johnson & Johnson Vision Care, INC. | $25.40 | 2019-2020 | |
| Allergan, INC. | $25.33 | 2021 | |
| Aerie Pharmaceuticals, INC. | $22.21 | 2021 | |
| Oyster Point Pharma, INC. | $20.13 | 2022 | |
| Rayner Intraocular Lenses Limited | $18.89 | 2022 | |
| Amgen INC. | $18.51 | 2024 | Tepezza |
| Apellis Pharmaceuticals, INC. | $17.83 | 2025 | Syfovre |
| Menicon America INC | $17.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Benoit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.